A randomised, double-blind, placebo-controlled parallel group, single centre study evaluating neurohumoral, haemodynamic and renal effects of UrocortiN 2 administered In addition to COnventional care compared with placebo administered in addition to standaRd care in subjects with Acute DecompeNsated Heart Failure.

Trial Profile

A randomised, double-blind, placebo-controlled parallel group, single centre study evaluating neurohumoral, haemodynamic and renal effects of UrocortiN 2 administered In addition to COnventional care compared with placebo administered in addition to standaRd care in subjects with Acute DecompeNsated Heart Failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Urocortin 2 (Primary)
  • Indications Decompensated heart failure
  • Focus Pharmacodynamics
  • Acronyms UNICORN
  • Most Recent Events

    • 17 May 2012 Results have been reported in a Neurocrine Biosciences media release.
    • 02 May 2012 Status changed from recruiting to completed, according to a Neurocrine Biosciences media release.
    • 03 May 2011 As of mid-April, 43 out of 50 patients have been enrolled, according to a Neurocrine Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top